Table 1.
Maximal contractile effect to PE, with and without l-NAME, and angiotensin in female and male KO, KOM, KOP, and WT at 7, 14, and 21 wk of age
| Agents | Age, wk | KOP | KOM | KO | WT |
|---|---|---|---|---|---|
| Females | |||||
| PE | 7 | 70.1 ± 6.2 | 84.6 ± 7.0 | 150.3 ± 6.9* | 97.2 ± 11.9 |
| 14 | 71.7 ± 8.1 | 153 ± 9.8# | 174.8 ± 1.9* | 102.2 ± 11.1 | |
| 21 | 77.5 ± 6.7 | 139 ± 6.1# | 172.7 ± 7.5* | 102.7 ± 10.8 | |
| PE + l-NAME | 7 | 142.4 ± 7.7 | 201.03 ± 1.2 | 202.57 ± 17.1 | 155.8 ± 19.9 |
| 14 | 173.1 ± 8.8* | 201.89 ± 3.8 | 237.08 ± 7.9 | 211.9 ± 10.7 | |
| 21 | 172.4 ± 5.1* | 226.2 ± 8.4 | 206 ± 8.8 | 214.6 ± 8.8 | |
| ANG | 7 | 0.9 ± 0.5 | 2.0 ± 0.6 | 2.9 ± 1.4 | 0.6 ± 0.07 |
| 14 | 2.1 ± 0.7 | 5.5 ± 2.3 | 6.1 ± 2.5 | 4.5 ± 1.9 | |
| 21 | 3.8 ± 0.8 | 5.13 ± 3.01 | 2.8 ± 12.7* | 3.3 ± 0.7 | |
| Males | |||||
| PE | 7 | 69.4 ± 4.6 | 80.2 ± 3.1 | 136.3 ± 3.5* | 89.2 ± 9.8 |
| 14 | 71.4 ± 8.9 | 133.6 ± 8.9# | 159.4 ± 9.4* | 89.6 ± 6.3 | |
| 21 | 84.7 ± 12.6 | 138.7 ± 6.7# | 164.3 ± 8.9* | 98.7 ± 9.9 | |
| PE+l-NAME | 7 | 164.4 ± 7.2 | 184.1 ± 9.1 | 212.3 ± 5.4 | 192.1 ± 9.6 |
| 14 | 174.7 ± 3.1 | 205.1 ± 8.1 | 225.7 ± 5.9 | 186.9 ± 17.3 | |
| 21 | 170.3 ± 7.3 | 191.4 ± 10.4 | 219.3 ± 17.1 | 208.4 ± 10 | |
| ANG | 7 | 0.11 ± 0.56 | −0.57 ± 0.36 | 9.0 ± 2.42* | 0.53 ± 0.31 |
| 14 | 1.54 ± 0.57 | 3.59 ± 1.30 | 13.2 ± 2.98* | 0.21 ± 0.85 | |
| 21 | 3.01 ± 0.94 | 4.76 ± 1.16 | 30.7 ± 6.2* | 2.76 ± 0.90 | |
Results are expressed as percent of the reference KCl contraction (mean ± SE). PE, phenylephrine; l-NAME, NG-nitro-l-arginine methyl ester; KO, knockout, WT. wild type; KOM, maternally derived heterozygous; KOP, paternally derived heterozygous; ANG, angiotensin. P < 0.05 for KO vs. WT, KOM, and KOP (*) and for KOM vs. WT and KOP (#)).